Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spina…
Drug Manufacturers - General
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 4.96 | 2.10 | 2.00 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -16.02 | 8.47 | 10.09 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 2.58 | 104.77 | 102.14 | |
| Cash | 2.12 | 7.40 | 7.25 | |
| Capex | -85.05 | -0.83 | -0.45 | |
| Free Cash Flow | 718.61 | 2.98 | -0.36 | |
| Revenue | -7.99 | 15.15 | 16.47 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -7.34 | 0.69 | 0.74 | |
| Operating Margin | 102.85 | 0.25 | 0.12 | |
| ROA | 59.19 | 0.01 | < 0.005 | |
| ROE | 53.27 | 0.03 | 0.02 | |
| ROIC | 88.74 | 0.02 | 0.01 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of BIIB is permitted for members.
5
Growth
The "Growth Entry" for the Focus of BIIB is permitted for members.
6
Leverage & Liquidity